Dutch court enjoins Ceban from compounding semaglutide nasal spray
The District Court The Hague held that resale to other pharmacies and G-Standard listing fall outside the Dutch patent law pharmacy exemption.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 6 03:00 ETSource: JUVE Patent
The wire
- 01The District Court The Hague granted Novo Nordisk a preliminary injunction against Breda pharmacy Ceban over its compounded semaglutide nasal spray Semanova, finding infringement of Dutch SPC 300936, in force until 19 March 2031.
- 02The ruling narrows how far European compounding pharmacies can go on semaglutide after the compound patent EP 1 863 839 expired in March, with stocking, resale and branding all outside the exemption.
- 03The judge noted Ceban imported 600 grams of semaglutide, enough for 15,000 vials, pointing to 'structural and potentially large-scale use'; this is preliminary relief, not a final merits decision.
From the source
Read at juve-patent.comDutch pharmacy exemption defence fails in Novo Nordisk semaglutide case
Ceban may not distribute a compounded semaglutide nasal spray in the Netherlands. The District Court The Hague has issued a preliminary injunction against the Dutch retail pharmacy. The court found that Ceban's activities infringed Novo Nordisk's SPC for semaglutide and rejected the pharmacy's reliance on the patent law pharmacy exemption in its broader form.